Patents by Inventor Johan Hansson
Johan Hansson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11943009Abstract: A communication barrier arrangement includes a first driver having a first interface for receiving signals from a first device destined for a second device, an isolation barrier including a first transformer for signal transfer and having a primary winding connected to the first driver and a secondary winding, a second driver connected to the secondary winding and having a first connection terminal for output of the signals towards the second device, a first signal conditioner having a second connection terminal for receiving the signals from the second driver and a second interface for delivering them to the second device and a protection circuit including a resistor in parallel with a first capacitor, the protection circuit being connected between the first and second connection terminals.Type: GrantFiled: July 1, 2022Date of Patent: March 26, 2024Inventors: Ulf Hansson, Thomas Keul, Johan Wennerberg
-
Patent number: 8915385Abstract: A coupler head for a coupling arrangement is shown, which coupler head includes a coupler head housing (6) extending in a longitudinal direction from a first end (6a), attachable to a drawbar, to a second end (6b), which is arranged to carry a coupling interface between coupled rail vehicles, which coupler head housing houses mechanical coupling components (8,9) effective for automatic coupling to the corresponding components of a connecting coupling arrangement. The coupler head is characterized in that the coupler head housing has at least one notch (11, 11?) for a predetermined and primarily axial compression thereof with absorption of energy from a deforming compressive force that is applied to the coupler head in the longitudinal direction thereof. The coupler head has preferably at least one notch (11, 11?) for a predetermined folding of the coupler head housing.Type: GrantFiled: June 8, 2011Date of Patent: December 23, 2014Assignee: Ego International B.V.Inventors: Johan Hansson, Mattias Hjort, Fredrik Hiswåls, Daniel Larsson, Anders Svedbo, Anders Westman
-
Publication number: 20130105431Abstract: A coupler head for a coupling arrangement is shown, which coupler head includes a coupler head housing (6) extending in a longitudinal direction from a first end (6a), attachable to a drawbar, to a second end (6b), which is arranged to carry a coupling interface between coupled rail vehicles, which coupler head housing houses mechanical coupling components (8,9) effective for automatic coupling to the corresponding components of a connecting coupling arrangement. The coupler head is characterized in that the coupler head housing has at least one notch (11, 11?) for a predetermined and primarily axial compression thereof with absorption of energy from a deforming compressive force that is applied to the coupler head in the longitudinal direction thereof. The coupler head has preferably at least one notch (11, 11?) for a predetermined folding of the coupler head housing.Type: ApplicationFiled: June 8, 2011Publication date: May 2, 2013Applicant: EGO INTERNATIONAL B.V.Inventors: Johan Hansson, Mattias Hjort, Fredrik Hiswåls, Daniel Larsson, Anders Svedbo, Anders Westman
-
Publication number: 20110136843Abstract: The present invention relates to a combination of (a) a chemokine receptor 1 (CCR1) antagonist and (b) a muscarinic antagonist. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treatment of airway diseases, such as chronic obstructive pulmonary disease (COPD) and asthma in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of airway diseases.Type: ApplicationFiled: February 21, 2008Publication date: June 9, 2011Inventors: Tomas Eriksson, Johan Hansson, Marguerite Mensonides-Harsema, John Mo
-
Publication number: 20110124613Abstract: The present invention provides a pharmaceutical product comprising, in combination of, (a) a (therapeutically effective) dose of a first active ingredient, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a (therapeutically effective) dose of a second active ingredient, which is a glucocorticoid receptor agonist; and optionally, (c) a (therapeutically effective) dose of a third active ingredient, which is a ?2-agonist. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treating treatment of airway diseases, especially chronic obstructive pulmonary disease (COPD) and asthma in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of airway diseases such as COPD and asthma.Type: ApplicationFiled: February 21, 2008Publication date: May 26, 2011Inventors: Tomas Eriksson, Johan Hansson, Marguerite Mensonides-Harsema, John Mo
-
Patent number: 7788983Abstract: A sensor arrangement is arranged to detect at least one position of a displaceable component in a fluid device, which fluid device comprises a wall enclosing a cavity, in which cavity the component is displaced by pressurized fluid selectively applied to the component. The sensor arrangement includes a magnetic sensor mounted outside the wall and a first sensor element that is connected to the magnetic sensor and extends through the wall and a predetermined distance into the cavity. The magnetic sensor is arranged to detect the position of at least one predetermined second sensor element located on the displaceable component by sensing a change in magnetic flux induced in the first sensor element by the second sensor element.Type: GrantFiled: April 9, 2009Date of Patent: September 7, 2010Assignee: Parker-Hannifin CorporationInventors: Johan Hansson, Ulf Nyberg
-
Publication number: 20090298875Abstract: The present invention provides pharmaceutical compositions comprising a ?2-agonist, and a compound of formula: wherein m, R1, R2, R3, and R4 are as defined in the specification, and their use in therapy.Type: ApplicationFiled: August 24, 2006Publication date: December 3, 2009Applicant: ASTRAZENECA ABInventors: Tomas Eriksson, Johan Hansson
-
Publication number: 20090261819Abstract: A sensor arrangement is arranged to detect at least one position of a displaceable component in a fluid device, which fluid device comprises a wall enclosing a cavity, in which cavity the component is displaced by pressurized fluid selectively applied to the component. The sensor arrangement includes a magnetic sensor mounted outside the wall and a first sensor element that is connected to the magnetic sensor and extends through the wall and a predetermined distance into the cavity. The magnetic sensor is arranged to detect the position of at least one predetermined second sensor element located on the displaceable component by sensing a change in magnetic flux induced in the first sensor element by the second sensor element.Type: ApplicationFiled: April 9, 2009Publication date: October 22, 2009Applicant: PARKER HANNIFIN ABInventors: Johan Hansson, Ulf Nyberg
-
Publication number: 20090215732Abstract: The present invention provides pharmaceutical compositions comprising a glucocorticosteroid and a compound of formula: wherein m, R1, R2, R3, and R4 are as defined in the specification, and their use in therapy.Type: ApplicationFiled: August 24, 2006Publication date: August 27, 2009Inventors: Tomas Eriksson, Johan Hansson
-
Patent number: 7226595Abstract: A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, preferably TCRV?, and T cell activation have been replaced by another amino acid residue while retaining the ability to activate a subset of T cells. In preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens. A therapeutic method making use of modified/chimeric superantigens as defined in the preceding paragraphs. An antibody preparation in which the cysteine residues that provide for interchain disulfide bonds have been mutated so as to forbid interchain disulfide bridges, preferably to serine residues, for use as pharmaceutical.Type: GrantFiled: October 30, 2002Date of Patent: June 5, 2007Assignee: Active Biotech A.B.Inventors: Per Antonsson, Per Bjork, Mikael Dohlsten, Terje Kalland, Lars Abrahmsen, Johan Hansson, Göran Forsberg
-
Publication number: 20060104204Abstract: A message that comprises encoded bits interleaved over N transmission bursts, wherein N is greater than 1, is received by receiving fewer than N of the transmission bursts, whereby there exist remaining ones of the N transmission bursts that have not been received. All of the received transmission bursts are decoded to generate decoded data. It is then determined whether the decoded data is error free. Reception of remaining transmission bursts of the message is inhibited if the decoded data is error free, otherwise one or more remaining ones of the N transmission bursts are received.Type: ApplicationFiled: November 12, 2004Publication date: May 18, 2006Inventors: Johan Hansson, Goran Pehrsson, Emma Wittenmark, Bjorn Rikte
-
Patent number: 6750656Abstract: A technique for estimating current consumption of an electronic device such that current consumed during reception of bursts is utilized in calculating the remaining battery power. By determining the time duration of each reception burst and the charge consumed during each burst, the total charge consumed by the reception bursts is calculated. The total charge calculated is used to determine the remaining battery power.Type: GrantFiled: September 10, 2002Date of Patent: June 15, 2004Assignee: Telefonaktiebolaget LM Ericsson(PUBL)Inventors: Kent-Inge Ingesson, Johan Hansson, Kristoffer Ptasinski
-
Publication number: 20040046565Abstract: A technique for estimating current consumption of an electronic device such that current consumed during reception of bursts is utilized in calculating the remaining battery power. By determining the time duration of each reception burst and the charge consumed during each burst, the total charge consumed by the reception bursts is calculated. The total charge calculated is used to determine the remaining battery power.Type: ApplicationFiled: September 10, 2002Publication date: March 11, 2004Inventors: Kent-Inge Ingesson, Johan Hansson, Kristoffer Ptasinski
-
Publication number: 20030092894Abstract: A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, preferably TCRV&bgr;, and T cell activation have been replaced by another amino acid residue while retaining the ability to activate a subset of T cells.Type: ApplicationFiled: October 30, 2002Publication date: May 15, 2003Applicant: Pharmacia AB, Uppsala SwedenInventors: Per Antonsson, Per Bjork, Mikael Dohlsten, Terje Kalland, Johan Hansson, Goran Forsberg, Lars Abrahmsen
-
Patent number: 6514498Abstract: A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, referably TCRV&bgr;, and T cell activation has been replaced by another amino acid residue while retaining the ability to activate a subset of T cells. In a preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens. A therapeutic method making use of modified/chimeric superantigens as defined in the preceding paragraphs.Type: GrantFiled: August 12, 1996Date of Patent: February 4, 2003Assignee: Pharmacia ABInventors: Per Antonsson, Per Björk, Mikael Dohlsten, Johan Hansson, Göran Forsberg, Lars Abrahmsén, Terje Kalland
-
Patent number: 5836950Abstract: The present invention relates to a guide instrument which is adapted for use at operations for fixation of bone fragments at bone fractures, preferably femoral neck fractures, whereby the bone fragments are intended to be fixed relative to each other by means of at least two bone screws, whereby the guide instrument (1) is adapted for guiding a first and a second drill steel which are adapted for drilling passages in the bone fragments for the bone screws. The guide instrument (1) is designed to permit guiding of the drill steels, driving through of threaded front portions of the bone screws and guiding of uptapped or unthreaded rear portions of said bone screws.Type: GrantFiled: May 13, 1997Date of Patent: November 17, 1998Inventor: Henrik Lars Johan Hansson